IN THE ABSTRACT:

Add the attached Abstract after the claims.

IN THE FIGURES:

Insert the attached new Figure 16.

IN THE CLAIMS:

Amend the claims 1-25 noted on pages 36-40 of the application as "MODIFIED PAGE" which were submitted as an amendment under Article 34 and are presently pending.

Claim 3, line 1, delete "or 2".

Claims 4-10, line 1, delete "any one of the preceding claims" and insert --claim 1--.

Claim 13, line 3, delete "any one of the preceding claims" and insert --claim 1--.

Claim 14, line 1, delete "17" and insert --13--.

Claim 15, line 4, delete "any one of the preceding claims" and insert --claim 1--.

Claim 17, lines 1-2, delete "any one of the preceding claims" and insert --claim 11--.

Claim 19, lines 1-2, delete "any one of claims 1 to 12" and insert --claim 1--.

Claim 20, line 2, delete "any one of claims 1 to 12" and insert --claim 1--; and

lines 11-12, delete "a polypeptide according to any one of claims 1 to 12" and insert --said polypeptide--.

21. (Amended) Pharmaceutical composition comprising, in association with a pharmaceutically acceptable vehicle, an effective amount of polypeptides according to claim 1 [any one of the preceding claims], or fragments of such polypeptides, or an effective amount of antibodies specific thereto [according to claim 13 or 14], or fragments of such antibodies, or an effective amount of nucleic acids encoding said polypeptides or fragments of said polypeptides [according to claim 15 or 16], or variants of such nucleic acids.

22. (Amended) *In vitro* method of diagnosing an abnormal or undesired function of a cell, characterized in that it comprises steps involving:

- bringing of at least one cell, or one cell extract, into contact with an antibody according to claim 13 [or 14], or a fragment of such an antibody, or with a nucleic acid which encodes a polypeptide which specifically binds to said antibody [according to claim 15 or 16], or a variant of such a nucleic acid, and

- revealing of the reaction product which may be formed.

23. (Amended) *In vitro* diagnostic method according to claim 22, characterized in that said abnormal or undesired function results in an immunoproliferative disease, an immunodeficiency disease such as an HIV disease, a cancer such as lymphoproliferative disease of the granular lymphocytes, an autoimmune disease such as rheumatoid arthritis, an infectious disease such as malaria, an allergic response or a graft reject.

24. (Amended) Method of identifying molecules which adaptor carryout the activation of a KAR, characterized in that it comprises steps involving:

i. bringing of the candidate molecules into contact with polypeptides according to [any one of claims 1 to 12] claim 1 (or with fragments of such polypeptides), and

ii. selection of those candidate molecules for which a binding to said polypeptides (or to said polypeptide fragments) is observed.

25. (Amended) Method of identifying molecules capable of modulating a cell activity resulting from the activation of a KAR, characterized in that it comprises steps involving:

i. bringing of the candidate molecules into contact with molecules which adapt or carry out the activation of a KAR, as obtained by the method according to claim 24, [and with polypeptides according to any one of claims 1 to 12 (or with fragments of such polypeptides)], and

ii. selection of those candidate molecules which exert an effect on the binding between said polypeptides (or said polypeptide fragments) and said adapter of effector molecules, as observed in the absence of said candidate molecules.

REMARKS

Favorable consideration of the attached and entry of the above amendments are requested.

The specification has been amended to insert the attached Sequence Listing. A paper and computer readable copy of the Sequence Listing are attached. The attached paper and computer copies of the Sequence Listing are the same. No new matter has been added.